In COVID-19 clinical update #66, Daniel Griffin covers treatment guidelines from IDSA, hospitalization of adolescents, estimating epidemiological dynamics from viral load distributions, incidence of infection according to baseline antibody status, assessment of reinfection in Italy, need for vaccination in previously infected individuals, assessment of protection against reinfection, antimicrobial use in hospitalized patients, effect of single dose ivermectin, and a trial of aspirin in hospitalized patients.
David joins TWiV to relate how his near-death experience with Castleman’s disease motivated him to found the Center for Cytokine Storm Treatment & Laboratory and the CORONA project to identify and track all treatments reported for COVID-19 in an open-source data repository.
In COVID-19 clinical update #65, Daniel Griffin summarizes effects of non-pharmaceutical interventions, updated summer camp guidance from CDC, serology testing not recommended by FDA, antigen tests during a music event, inhibition of vaccine immunogenicity by methotrexate, phase 3 trial results for colchicine, and small airway disease as a post-acute sequelae.
In COVID-19 clinical update #64, Daniel Griffin covers new guidance from NY on day camps, mitigation and infection rates in schools, testing to sustain in person instruction, Moderna mRNA vaccine highly effective in adolescents, longer storage of Pfizer vaccine, FDA EUA for sotrovimab, and persistent illness in UK children.
In COVID-19 clinical update #60, Daniel Griffin summarizes CDC guidance for summer camps, how to protect yourself when fully vaccinated, updated recommendation for J&J vaccine, declining global case fatality rate, and characterization of post-acute sequelae.
In COVID-19 clinical update #57, Daniel Griffin covers children and MIS-C, school opening plans, transmission event with masks, fomite transmission, diagnostic test performance, AZ vaccine and blood clots, and long COVID and the effect of vaccines.
Arturo Casadevall joins TWiV to discuss the use of convalescent plasma to treat COVID-19, including a history of the process, how plasma is prepared and tested, why it is difficult to conduct randomized clinical trials, how this treatment has fared and his hopes for the future.
In COVID-19 clinical update #56, Daniel Griffin notes increasing hospitalization in children and young adults, Pfizer vaccine efficacy results in 12-15 year olds, rapid self administered nucleic acid and antigen tests, mRNA vaccine efficacy in real world conditions, and improvement of long COVID after vaccination.
Alessandro Sette joins TWiV to discuss the role of T cells in COVID-19, the finding that amino acid changes in SARS-CoV-2 variants of concern have a negligible impact on T cell reactivity in convalescent patients and vaccinees, and whether a next generation vaccine should include more viral proteins than spike.
In COVID-19 clinical update #55, Daniel Griffin reviews recommendations for keeping transmission low in school settings, optimal testing strategies for schools and businesses, impact of vaccines on asymptomatic infections, vaccine safety in PASC patients, and early use of aspirin associated with decreased mortality.